Brandon Scalea

Steven N. Kalkanis, MD, explains how next-generation sequencing testing fits into cancer treatment today and efforts that need to be made to enable its widespread use in the future.

Anthony Shields, MD, PhD, shares recent efforts being made with immunotherapy research in colorectal cancer, stressed the importance of molecular testing, and shed light on the use of liquid biopsies in the space.

Lauren Nye, MD, discusses the promise of neratinib in patients with early HER2-positive breast cancer, as well as ways to ease concern of associated toxicity.

Michel Velez, MD, addresses how loperamide and other methods of prophylaxis are significantly reducing the risk of neratinib-associated diarrhea in patients with HER2-positive breast cancer.

Nirav N. Shah, MD, discusses the promise of CAR T-cell therapy in hematologic malignancies and highlights recent research exploring sequential CAR-T therapies, armored CAR T cells, as well as other novel approaches.

Parameswaran Hari, MD, MRCP, discusses the rapidly evolving paradigm of myeloma with a focus on the latest updates in the frontline setting.

Sayeh Lavasani, MD, MS, discusses the application of gene assays in the management of patients with hormone receptor-positive breast cancer, as well as ongoing research in this space.

Scott Kopetz, MD, PhD, FACP, explains the biologic difference between left- and right-sided colorectal cancer and highlights recent research on tumor sidedness and its impact on clinical practice.

Saurabh Chhabra, MD, MS, highlights emerging agents in the field of relapsed/refractory myeloma that have oncologists optimistic for the future.

Laura Michaelis, MD, highlights the many ruxolitinib combinations under investigation and provided insight into the role of interferon in myeloproliferative neoplasms.

Lowell B. Anthony, MD, FACP, sheds light on important data that have shaped the current neuroendocrine tumors treatment paradigm and highlights notable ongoing studies.

Timothy Fenske, MD, MS, discusses promising ongoing research in mantle cell lymphoma that will look to further advanced the evolving paradigm.

Nathan T. Connell, MD, MPH, shares key updates in the rapidly evolving treatment paradigms of benign hematologic disorders.

Ronan J. Kelly, MD, MBA, addresses the paradigm shift in stage III unresectable non–small cell lung cancer before delving into the complex field of ALK-rearranged disease.

Eric S. Nadler, MD, discusses key data with immunotherapy in the treatment of patients with metastatic squamous non–small cell lung cancer.

Kristen Ciombor, MD, MSCI, discusses the promise of liquid biopsies in the rapidly evolving metastatic colorectal cancer paradigm and the potential implications of the COLOMATE trial.

Geoffrey Y. Ku, MD, discusses data of durvalumab plus tremelimumab in a biomarker-selected patient population and sheds light on the role of immunotherapy in patients with advanced gastric cancer.

Marcus Smith Noel, MD, discusses the early promise of SM-88 in the metastatic pancreatic cancer treatment landscape.

Michael J. Overman, MD, discusses an immunotherapy combination regimen in metastatic colorectal cancer and highlights existing challenges that still need to be addressed in future research.

Leonard G. Gomella, MD, underscores the need for genetic testing in prostate cancer, sheds light on important biomarkers in the space, and explains how these tests are helping oncologists facilitate a precision medicine approach.

Aaron S. Mansfield, MD, discusses recent progress in small cell lung cancer and remaining challenges in the field.

Neeraj Agarwal, MD, discusses the recent encouraging data reported in mRCC and highlighted the next steps needed to move the needle forward in this space.

Robert A. Figlin, MD, highlights advances made with immunotherapy in renal cell carcinoma and sheds light on the challenges that remain.

Lecia V. Sequist, MD, highlights the expansion cohort data from the TATTON study and explains how these findings could impact the treatment landscape of EGFR-mutant NSCLC.

Mark D. Pegram, MD, highlights data from pivotal studies that have helped to shape the current landscape of HER2-positive breast cancer and sheds light on emerging agents that are showing promise in the pipeline.

Margaret A. Tempero, MD, discusses the impact of FOLFIRINOX in the treatment of patients with metastatic pancreatic cancer and sheds light on the importance of molecular profiling in the space.

Orazio Caffo, MD, discusses the CHEIRON trial findings and their implications on the treatment paradigm in metastatic castration-resistant prostate cancer.

Derek R. McHaffie, MD, discusses the role of radiation therapy in the treatment of gastrointestinal cancers and the impact of radionuclide therapy in patients with neuroendocrine tumors.

David I. Quinn, PhD, MBBS, discusses the molecular diagnosis of renal cell carcinoma and also highlights emerging therapies in the treatment of patients with different subtypes of prostate cancer.

Joseph D. Rosenblatt, MD, discusses how advances made in chronic lymphocytic leukemia are changing the outlook for patients and predicts what can be accomplished in the near future.